BlueBird Bio: +ve Lyfgenia data release & the reverse stock split. Up 7% pre-market.
HTML-код
- Опубликовано: 12 дек 2024
- Greetings, fellow investors! Welcome back to ShareTreck. Here is what you need to know about why Bluebird bio (BLUE) stock and their latest positive data release on Lyfgenia. Beware of the impending 1:20 reverse stock split. take a listen and comment.
Well this is my personal opinion, not financial advice.
JOIN THE CHANNEL AS A MEMBER:
Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen or copy the link below to your browser address bar and press enter.
/ @sharetreck
Please subscribe: / @sharetreck
The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
In case of coverage of pharma companies, disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.
Blubird bio is coming back strong.
I’ve put a limit order to sell all my Bluebird bio shares before the split. Hopefully it hits my target before the split.
Thanks for sharing. Are you making any profit?
@@ShareTreckNo! My cost basis is $1.01 so hoping it goes above and fills the limit order. Would be breakeven. Don’t have faith after RS, shorts will be back again.
@MAK11-11 I feel your pain my friend. Good luck!!
@@ShareTreckThank You. 🙏